Preliminary and indirect evidence that mGluR5 antagonist can improve sociability in FXS (Burket et al., 2014) raises hopes that drugs targeting the mGluR5 might be of clinical use in prevalent psychiatric conditions associated with impaired systems for social processes such as autism, schizophrenia, and depression. Here, GRM5 is linked to major depressive disorder.